This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving (ALCDrive)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Mario Moric, Rush University Medical Center Identifier:
First received: November 14, 2007
Last updated: November 8, 2016
Last verified: November 2016
The proposed study will validate and determine sensitivity of our new driving simulator, created to evaluate driving ability in a related study to show similar driving performance between patients on chronic opioid treatment and a control group. Although the commercial version of the simulator has been validated for certain populations and certain measures, these require re-calibration for our own clinical study. The investigators propose a prospective randomized clinical trial to evaluate driving skills under alcohol consumption using a driving simulator. Two groups of study subjects will be utilized, with the majority (80%) receiving alcohol and placebo at different times. A smaller set of study subjects (20%) will be given placebo on both trials to evaluate learning effects and placebo blinding effectiveness. Each group will take the driving test at three time points: once as a baseline at the beginning of the study, once after the 1st dosing of the placebo and again after dosing two of the alcohol or placebo beverage. This information will allow us to evaluate driving ability under other potentially impairing conditions such as opioid usage.

Condition Intervention Phase
Driving Intoxication Impairment Alcohol Impaired Driving Drug: placebo Drug: Alcohol Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Validation of Driving Simulator Measures and Calibration to Blood Alcohol Concentration Standards for Impaired Driving

Further study details as provided by Mario Moric, Rush University Medical Center:

Primary Outcome Measures:
  • Weaving (Standard Deviation of Lateral Deviation) [ Time Frame: 6 h ]

Secondary Outcome Measures:
  • Reaction Time (RT) to unexpected stimuli, and number of accidents [ Time Frame: 6 h ]

Estimated Enrollment: 40
Study Start Date: February 2008
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Alcohol
Drug: Alcohol
Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
Other Name: Vodka
Placebo Comparator: Placebo
Orange juice
Drug: placebo
Placebo (orange juice), same volume as alcohol
Other Name: Orange Juice

Detailed Description:

Subjects will be recruited via discreet flyers distributed around the Rush University Medical Campus. Subjects will be scheduled so that a maximum of 6 participants are evaluated on the same day. Some evaluation days may fall on the weekend. Study duration is estimated at 4-5 hours, and at the completion the subjects will be driven to their respective residences.

Upon arrival subjects will complete questionnaires which contain demographic information and measures to evaluate possible alcohol abuse issues. All subjects will be given a short driving simulator practice and then the baseline simulator trial. Subjects will be randomized into two groups as part of a study, with an 80% probability of selection for group A and a 20% probability of selection for Group P. Group P will only be given placebos so that any learning effects can be estimated. In addition to the baseline, both groups will take the full driving test two additional times each preceded by an alcohol or placebo dosing. Of these two trials only on Trial#2 of Group A is alcohol given. Both groups will receiver placebo on simulator Trial #1.

Alcohol trial (Group A only):

The alcohol dose will consist of a 40% alcohol (vodka) liquor in a beverage containing 2 parts orange juice and 1 part liquor. The exact amount/volume of alcohol will be determined based on factors such as weight and sex so as to reach a peak BAC of 0.08%.

The primary contrast of interest is the comparison between the placebo and the alcohol dosed driving simulation trials. Analyses will take place with general linear models framework, using "Proc Mixed" to model the repeated measures design and produce accurate estimate of the pre-planned comparisons as well as main effects and longitudinal estimates. Various outcome variables that measure driving ability will be used, the three primary measures being: a measure of weaving (Standard Deviation of Lateral Deviation), Reaction Time (RT) to unexpected stimuli, and number of accidents. The placebo, Group P, will be evaluated to estimate the effect of learning and to estimate the effectiveness of the placebo sham.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Legal drinking age (=> 21).
  2. Moderate alcohol consumption

    • Defined as: at least 1 unit per week but less than 20 units per week. (unit = 12 oz. beer or equivalent).
  3. Current driver's license.
  4. Subjects can understand and communicate in English.

Exclusion Criteria:

  1. Known alcoholic or drug abuser.
  2. Alcohol naïve.
  3. Use of medications that may be aggravated (or contraindicated) by alcohol.
  4. Pregnant or breast feeding.
  5. Younger than 21 years or older than 80 years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00559819

United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Study Director: Asokumar Buvanendran, MD Rush University Medical Center
  More Information

Responsible Party: Mario Moric, Research Coordinator, Rush University Medical Center Identifier: NCT00559819     History of Changes
Other Study ID Numbers: MMoric111207
Study First Received: November 14, 2007
Last Updated: November 8, 2016

Keywords provided by Mario Moric, Rush University Medical Center:

Additional relevant MeSH terms:
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs processed this record on July 19, 2017